|1.||Cass, Carol E: 1 article (08/2010)|
|2.||Mowles, Delores: 1 article (08/2010)|
|3.||Damaraju, Vijaya L: 1 article (08/2010)|
|4.||Robins, Morris J: 1 article (08/2010)|
|5.||Tackaberry, Tracey: 1 article (08/2010)|
|6.||Young, James D: 1 article (08/2010)|
|7.||Peng, Yunshan: 1 article (08/2010)|
|8.||Barron, Geraldine: 1 article (08/2010)|
|9.||Kull, Thomas: 1 article (09/2009)|
|10.||Zlatopolskiy, Boris D: 1 article (09/2009)|
09/01/2009 - "Three new potential hENT(1) inhibitors suitable for labeling with PET/SPECT radioisotopes were prepared from an advanced intermediate 4. They were tested for their capability to inhibit binding of SAENTA-fluorescein to HL60 leukemia cells in flow cytometry assay and SAENTA-I (5) was determined to be the most active compound. "
07/01/1997 - "Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein."
|2.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
|3.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
08/26/2010 - "Conjugation of the pendant amino groups of SAENTA and SAHENTA with fluorescein-5-yl isothiocyanate (FITC) gave fluorescent probes that bound at nanomolar concentrations specifically to human equilibrative nucleoside transporter 1 (hENT1) produced in recombinant form in model expression systems and in native form in cancer cell lines. "
|2.||Equilibrative Nucleoside Transporter 1
|3.||Nucleoside Transport Proteins (Nucleoside Transporter)
|6.||Fluorescent Dyes (Fluorescent Probes)